Antiplatelet therapy for peripheral arterial disease and claudication

Vascular Medicine

Volumn 11, Issue 1, 2006, Pages 55-60

  Hiatt, William R ^a,b   Krantz, Mori J ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Colorado Prevention Center ^*  (United States)

Author keywords

Antiplatelet therapy; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; PENTOXIFYLLINE; PICOTAMIDE; TICLOPIDINE; DRUG DERIVATIVE; PHTHALIC ACID DERIVATIVE;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BONE MARROW SUPPRESSION; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG COST; DRUG MECHANISM; DYSLIPIDEMIA; EARLY DIAGNOSIS; EXERCISE; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LEG DISEASE; LIPID BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MEDICAL SOCIETY; META ANALYSIS; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; INTERMITTENT CLAUDICATION; LEG; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE AGGREGATION; VASCULARIZATION;

ASPIRIN; ATHEROSCLEROSIS; DRUG THERAPY, COMBINATION; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; META-ANALYSIS; PERIPHERAL VASCULAR DISEASES; PHTHALIC ACIDS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 33646142277     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x06vm653xx     Document Type: Article

References (34)

1. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970; 41: 875-83.
2. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282-90.
3. American Heart Association, Stroke and Statistical Update 2004. Available at: http://www.americanheart.org/presenter.jhtml?identifier=4478 and http://www.americanheart.org/presenter.jhtml?identifier=4725
4. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2: 221-26.
5. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-49.
6. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 1255-56.
7. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
8. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Oilong Y, Yusuf S. HOPE study investigators Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17-24.
9. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J. American Heart Association. AHA Conference Proceedings. Atherosclerotic Vascular Disease Conference. Writing Group III: Pathophysiology. Circulation 2004; 109: 2617-25.
10. Hansson G. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
11. Holme PA, Orvim U, Hamers MJ, Solum No, Brosstad FR, Barstad RM, Sakariassen KS. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-53.
12. Ferguson JJ, Quinn M, Moake JL. Platelet physiology. In: Ferguson JJ III, Chronos NAF, Harrington RA eds. Antiplatelet therapy in clinical practice. Martin Dunitz, 2000: 15-34.
13. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-64S.
14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
15. Antithrombotic Trialists' Collaboration. Collaborative meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86. Erratum in: BMJ 2002; 324: 141.
16. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
17. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
18. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 609S-26S.
19. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87: 1563-69.
20. Cocozza M, Picano T, Olivero U, Russo N, Coto V, Milani M. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 1995; 26: 597-601.
21. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-52.
22. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
23. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grosselli S, Violi F, Hellemans H, Vanhove P. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989; 114: 84-91.
24. Arcan JC, Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Hemost 1989; 15: 167-70.
25. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-29.
26. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
27. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346: 1800-806.
28. Second European Stroke Prevention Study. ESPS-2 Working Group. J Neurol 1992; 239: 299-301.
29. Diener H-C, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-37.
30. Gerschutz GP, Bhatt DL. Clopidogrel in Unstable Angina to Prevent Recurrent Events Study. The clopidogrel in unstable angina to prevent recurrent events (CURIE) study: to what extent should the results be generalized? Am Heart J 2003; 145: 595-601.
31. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
32. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001; 119 (1 suppl): 283S-99S.
33. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996; 82: 523-32.
34. PDR® entry for Plavix Tablets (Bristol-Myers Squibb). 2001. Available at: http://www.pdr.net